Abstract:Mental illnesses put a tremendous burden on afflicted individuals and society. Identification of novel drugs to treat such conditions is intrinsically challenging due to the complexity of neuropsychiatric diseases and the need for a systems-level understanding that goes beyond single molecule-target interactions. Thus far, drug discovery approaches focused on target-based in silico or in vitro high-throughput screening (HTS) have had limited success because they cannot capture pathway interactions or predict how a compound will affect the whole organism. Organismal behavioral testing is needed to fill the gap, but mammalian studies are too time-consuming and cost-prohibitive for the early stages of drug discovery. Behavioral HTS in small organisms promises to address this need and complement in silico and in vitro HTS to improve the discovery of novel neuroactive compounds. Here, we used cheminformatics and HTS in the freshwater planarian Dugesia japonica - an invertebrate system used for neurotoxicant HTS - to evaluate the extent to which complementary insight could be gained from the two data streams. In this pilot study, our goal was to classify 19 neuroactive compounds into their functional categories: antipsychotics, anxiolytics, and antidepressants. Drug classification was performed with the same computational methods, using either physicochemical descriptors or planarian behavioral profiling. As it was not obvious a priori which classification method was most suited to this task, we compared the performance of four classification approaches. We used principal coordinate analysis or uniform manifold approximation and projection, each coupled with linear discriminant analysis, and two types of machine learning models - artificial neural net ensembles and support vector machines. Classification based on physicochemical properties had comparable accuracy to classification based on planarian profiling, especially with the machine learning models that all had accuracies of 90-100%. Planarian behavioral HTS correctly identified drugs with multiple therapeutic uses, thus yielding additional information compared to cheminformatics. Given that planarian behavioral HTS is an inexpensive true 3R (refine, reduce, replace) alternative to vertebrate testing and requires zero a priori knowledge about a chemical, it is a promising experimental system to complement in silico HTS to identify new drug candidates.

From systems biology to dynamical neuropharmacology: proposal for a new methodology

Physiologically informed neuromodulation

Changing Brain Networks Through Non-invasive Neuromodulation

Quantitative systems pharmacology in neuroscience: Novel methodologies and technologies

Affective Disorders as Complex Dynamic Diseases – a Perspective from Systems Biology

High-throughput brain activity mapping and machine learning as a foundation for systems neuropharmacology

Brain States and Transitions: Insights from Computational Neuroscience

Dynamic Modeling of Neuromodulation Techniques: Towards Elaboration and Individual Specificity

Computational Psychopharmacology: a Translational and Pragmatic Approach

Dynamical systems in computational psychiatry: A toy-model to apprehend the dynamics of psychiatric symptoms

Investigating Targets for Neuropharmacological Intervention by Molecular Dynamics Simulations

Neuromorphic computing for modeling neurological and psychiatric disorders: implications for drug development

Sleep, Neuroengineering and Dynamics

Use of quantitative clinical pharmacology to improve early clinical development success in neurodegenerative diseases

Whole brain modelling for simulating pharmacological interventions on patients with disorders of consciousness

Challenges and Frontiers in Computational Metabolic Psychiatry

Computational non-linear dynamical psychiatry: A new methodological paradigm for diagnosis and course of illness

Distinguishing classes of neuroactive drugs based on computational physicochemical properties and experimental phenotypic profiling in planarians

An integrated microfluidic and fluorescence platform for probing in vivo neuropharmacology

Deep Network Pharmacology: Targeting Glutamate Systems as Integrative Treatments for Jump-Starting Neural Networks and Recovery Trajectories

Solving the crisis in psychopharmacological research: Cellular-membrane(s) pharmacology to the rescue?